MA71665A - Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation - Google Patents

Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Info

Publication number
MA71665A
MA71665A MA71665A MA71665A MA71665A MA 71665 A MA71665 A MA 71665A MA 71665 A MA71665 A MA 71665A MA 71665 A MA71665 A MA 71665A MA 71665 A MA71665 A MA 71665A
Authority
MA
Morocco
Prior art keywords
methods
fusion proteins
transferrin receptor
receptor fusion
transferrin
Prior art date
Application number
MA71665A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Junhua Wang
Annie ARGUELLO
Tina GIESE
Mihalis S. Kariolis
Cathal S. Mahon
Original Assignee
Denali Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc. filed Critical Denali Therapeutics Inc.
Publication of MA71665A publication Critical patent/MA71665A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA71665A 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation MA71665A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148543P 2021-02-11 2021-02-11
PCT/US2022/016229 WO2022174114A1 (fr) 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
EP22753465.8A EP4291246A4 (fr) 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA71665A true MA71665A (fr) 2025-05-30

Family

ID=82837358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71665A MA71665A (fr) 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Country Status (6)

Country Link
US (3) US20240148866A1 (fr)
EP (1) EP4291246A4 (fr)
JP (1) JP2024507118A (fr)
CN (1) CN116997364A (fr)
MA (1) MA71665A (fr)
WO (1) WO2022174114A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71665A (fr) 2021-02-11 2025-05-30 Denali Therapeutics Inc. Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
US20260015409A1 (en) * 2022-09-20 2026-01-15 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos
TW202432602A (zh) 2022-12-05 2024-08-16 法商賽諾菲公司 運鐵蛋白受體結合蛋白
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032913A2 (fr) * 2001-10-16 2003-04-24 Symbiontics Inc. Procedes et compositions pour le ciblage de proteines a travers la barriere hemato-encephalique (bhe)
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Fc融合タンパク質の精製方法
JP6616189B2 (ja) * 2013-12-25 2019-12-04 Jcrファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
CA2990785C (fr) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. Anticorps anti-recepteur de transferrine humaine passant au travers de la barriere hematoencephalique
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
BR112020005271A2 (pt) * 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸-2-スルファターゼ免疫グロブリン融合タンパク質の精製
MA71665A (fr) 2021-02-11 2025-05-30 Denali Therapeutics Inc. Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US20250387477A1 (en) 2025-12-25
JP2024507118A (ja) 2024-02-16
US12636363B2 (en) 2026-05-26
EP4291246A4 (fr) 2024-12-11
US20240148866A1 (en) 2024-05-09
US20250367284A1 (en) 2025-12-04
EP4291246A1 (fr) 2023-12-20
WO2022174114A1 (fr) 2022-08-18
CN116997364A (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
MA52390A (fr) Anticorps anti-coronavirus et procédés d'utilisation
EP3962497A4 (fr) Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation
MA56074A (fr) Anticorps contre le sars-cov-2 et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP4236990A4 (fr) Variants de l'interleukine-18 et leurs procédés d'utilisation
EP3980067A4 (fr) Protéine de fusion anticorps-interleukine et procédés d'utilisation
EP4161967A4 (fr) Protéines de ciblage de b7h3 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3947688A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
MA51676A (fr) Protéines de fusion il-22 fc et procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP4177265A4 (fr) Anticorps d'iga reconnaissant spécifiquement une protéine rbd et kit de test
EP3994275A4 (fr) Sialidases humaines recombinantes, protéines de fusion de sialidases et leurs procédés d'utilisation
EP3873941A4 (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés
EP4003378A4 (fr) Banques de lymphocytes t spécifiques de l'antigène et leurs procédés de fabrication et d'utilisation thérapeutique
EP3873939A4 (fr) Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation
EP4121458A4 (fr) Protéines de type anticorps de régulation de guidage et de navigation (gnc) et leurs procédés de production et d'utilisation
EP3938400A4 (fr) Anticorps cd22 et leurs procédés d'utilisation
EP3935172A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3935176A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP4061847A4 (fr) Anticorps monoclonal anti-b7-h3 et ses procédés d'utilisation
EP4153618A4 (fr) Récepteurs de lymphocytes t modifiés et leurs procédés d'utilisation
EP3966248A4 (fr) Anticorps humanisés dirigés contre la mucine-16 et leurs procédés d'utilisation
EP4048402A4 (fr) Lymphocytes t cytoxiques modifiés et leurs procédés d'utilisation
EP3947452A4 (fr) Anticorps anti-récepteur nmda et procédés d'utilisation